|
We currently have six programs focused on inflammation, all targeting large markets.
Our most clinically advanced product candidates in the area of inflammation are derived from our proprietary PharmacoSurgery platform, designed to improve the clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Our MASP-2 and Chondroprotective programs, targeting multiple inflammatory disorders and arthritis, respectively, are in preclinical development.
• PharmacoSurgeryTM
• MASP-2
• Chondroprotective
|
